title: [High-dose intravenous immunoglobulin treatment].
abstract: Intravenous immunoglobulin treatment was introduced as replacement therapy for patients with congenital agammaglobulinemia. For the last three decades, high-dose intravenous immunoglobulin (HD-IVIg) has been used for autoimmune diseases and systemic inflammatory diseases, such as idiopathic thrombocytopenic purpura, Kawasaki disease, myasthenia gravis and Guillain-Barré/syndrome. Although the immunomodulatory mechanisms of HD-IVIg remains unclear. Its use in many other diseases have been expected. Acute encephalitis/encephalopathy is a complex neurological syndrome associated with significant morbidity and mortality. The pathogenicity of brain dysfunction is still unknown. This review provides an overview and discussion of mechanisms that may be responsible for HD-IVIg effects in acute encephalitis/encephalopathy.
authors.affiliation: Department of Pediatrics, Faculty of Medicine, University of Toyama.
authors.forename: Hiromichi
authors.initials: H
authors.lastname: Taneichi
authors.forename: Toshio
authors.initials: T
authors.lastname: Miyawaki
mesh_terms: D000208:Acute Disease; D001927:Brain Diseases / Q000188:drug therapy*; D004660:Encephalitis / Q000188:drug therapy*; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage*
chemical_list: D016756:Immunoglobulins, Intravenous